Across TCGA pan-cancer cohorts, LCE3E Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LCE3E data layer compared with 16 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LCE3E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LCE3E expression acts as an unfavorable survival marker.

STAD, UCEC, and SCLC are the cancer types where LCE3E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.074	0.660	<.001	30	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LCE3E tumor-vs-normal RNA expression · all LCE3E data types